Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash from Financing Activities for 6 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 2714.42% to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$48.5 million, a 120.35% decrease, with the full-year FY2025 number at -$48.5 million, down 120.35% from a year prior.
  • Cash from Financing Activities was -$2.9 million for Q4 2025 at Lexicon Pharmaceuticals, up from -$45.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $239.4 million in Q1 2024 to a low of -$45.0 million in Q2 2025.
  • A 3-year average of $34.3 million and a median of -$210000.0 in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 29151.33% in 2024, then crashed 321328.57% in 2025.
  • Lexicon Pharmaceuticals' Cash from Financing Activities stood at -$1000.0 in 2023, then plummeted by 10300.0% to -$104000.0 in 2024, then plummeted by 2714.42% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Cash from Financing Activities are -$2.9 million (Q4 2025), -$45.0 million (Q2 2025), and -$572000.0 (Q1 2025).